FOLLISTATIN-344 - 1mg

SPECIFICATIONS

Product Code: FO3001

Sequence: MVRARHQPGG LCLLLLLLCQ FMEDRSAQAG NCWLRQAKNG RCQVLYKTEL SKEECCSTGR LSTSWTEEDV NDNTLFKWMI FNGGAPNCIP CKETCENVDC GPGKKCRMNK KNKPRCVCAP DCSNITWKGP VCGLDGKTYR NECALLKARC KEQPELEVQY QGRCKKTCRD VFCPGSSTCV VDQTNNAYCV TCNRICPEPA SSEQYLCGND GVTYSSACHL RKATCLLGRS IGLAYEGKCI KAKSCEDIQC TGGKKCLWDF KVGRGRCSLC DELCPDSKSD EPVCASDNAT YASECAMKEA ACSSGVLLEV KHSGSCNSIS EDTEEEEEDE DQDYSFPISS ILEW

Molecular Weight: 3780 g/mol

PubChem CID: 178101631

Purity: Technical / Research Grade 98%

Other Details: No TFA Salt

Form: Lyophilized powder

Color: White

Storage Temperature: -20°C

Source: Synthetic

Safety Classification: Standard handling

DESCRIPTION

Follistatin (FST-344) is a laboratory-produced analogue of the naturally occurring human follistatin protein. In preclinical and experimental research, it has been investigated for its interactions with members of the TGF-β superfamily, including myostatin, activins, and follicle-stimulating hormone (FSH), which are involved in growth regulation, tissue differentiation, and cellular signaling.

Within experimental models, follistatin has been shown to modulate signaling pathways associated with:

• Regulation of cellular differentiation and tissue development processes
• Maintenance of tissue integrity in experimental models of age-related and stress-induced conditions
• Interaction with signaling mechanisms related to metabolic and endocrine pathways
• Regulation of energy-related signaling processes in controlled research environments
• Modulation of cellular development pathways in adipose and connective tissue research
• Fibrosis-associated signaling, particularly in hepatic tissue models
• Reproductive system signaling involving activin-mediated pathways
• Cell migration and intercellular communication processes explored in advanced research contexts
• Hair follicle-related signaling investigated in limited experimental models.

These findings derive from in vitro experiments and animal studies. Follistatin-344 is used exclusively as a research tool for investigating biological mechanisms related to tissue remodeling, endocrine signaling, cellular regulation, and growth-associated pathways.

REFERENCES

All information presented above is derived from in vitro experiments, animal studies, and other preclinical research models. These data are intended solely for basic scientific investigation of biological mechanisms and do not imply any therapeutic, diagnostic, preventive, or clinical use in humans or animals.

H. Gilson et al., "Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin" [PubMed]

L.R. Rodino-Klapac et al., "Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease" [PubMed]

S. Muttukrishna et al., "Serum activin A and follistatin in disorders of spermatogenesis in men" [PubMed]

R. Wijayarathna et al., "Activins in reproductive biology and beyond" [PubMed]

J. Kota et al., "Follistatin gene delivery enhances muscle growth and strength in nonhuman primates" [PubMed]

L. Grobet et al., "Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene" [PubMed]

R.A. Anderson et al., "Follistatin and activin A production by the male reproductive tract" [PubMed]

Se-Jin Lee et al., "Regulation of Muscle Mass by Follistatin and Activins" [Molecular Endocrinology]

A. Iskenderian et al., "Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone" [PubMed]

T.K. Woodruff et al., "Activin A and follistatin are dynamically regulated during human pregnancy" [PubMed]

M.W. Hamrick et al., "Resistance to body fat gain in 'double-muscled' mice fed a high-fat diet" [PubMed]

J. Hansen et al., "Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine" [PubMed]

M. Nakatani et al., "Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis" [PubMed]

M. Sharp et al., "The effects of a myostatin inhibitor on lean body mass, strength, and power in resistance trained males" [PubMed]

C. Barbé et al., "Role of IGF-I in follistatin-induced skeletal muscle hypertrophy" [PubMed]

C. Zabkiewicz et al., "Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival" [PubMed]

D.D. Seachrist et al., "Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer" [BMC]

L. Shi et al., "Clinical and Therapeutic Implications of Follistatin in Solid Tumours" [PubMed]

C. Zhao et al., "Overcoming Insulin Insufficiency by Forced Follistatin Expression in β-cells of db/db Mice" [PubMed]

DISCLAIMER

This product is intended strictly for laboratory research and development use only. This material is not a medicine or drug and has not been evaluated or approved by the FDA, EMA, or any regulatory authority for the prevention, treatment, or cure of any medical condition or disease. Any form of administration to humans or animals is strictly prohibited. Handling is restricted to qualified laboratory professionals.

All product information provided on this website is for informational and educational purposes only.